TIDMOXB
RNS Number : 3379F
Oxford Biomedica PLC
15 July 2021
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive
Director
Oxford, UK - 15 July, 2021: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, is pleased to announce that Dr. Michael Hayden has
been appointed to the Group's Board as a Non-Executive Director,
effective today.
Dr. Hayden was the President of Global R&D and Chief
Scientific Officer at Teva Pharmaceuticals Industries Ltd. from
2012 to 2017 during which time approximately 35 new products were
approved in major markets. In 2015 Teva R&D was recognised as
one of the ten most exciting innovators in the pharma sector and in
2017 it was ranked top of the industry for CNS development and
clinical trial success rate by Pharma Intelligence.(1)
Dr. Hayden is the co-founder of five biotechnology companies:
Prilenia Therapeutics B.V., NeuroVir Therapeutics Inc., Xenon
Pharmaceuticals Inc., Aspreva Pharmaceuticals Corp and 89bio, Inc.
He currently represents various private biotech companies at Board
level and serves as CEO of Prilenia Therapeutics, which is a
private company focussed on the neurology space. In addition he is,
or has been, on the Board of the following public companies in the
last five years: 89bio, Inc., AbCellera Biologics Inc., Aurinia
Pharmaceuticals Inc (until 30 June 2021), Ionis Pharmaceuticals,
Inc. and Xenon Pharmaceuticals Inc.
Dr. Hayden has previously been cited as one of the 50 Canadians
born in the 20th century to have changed the world(2) , and in 2017
was inducted into the Canadian Medical Hall of Fame. He has
authored approximately 900 peer-reviewed publications and invited
submissions, and has focused his research primarily on
translational medicine, including genetics of diabetes, lipoprotein
disorders, Huntington's disease, predictive and personalised
medicine, and drug development. Dr. Hayden and his research group
have identified 10 disease-causing genes which includes the
identification of the major gene underlying high-density
lipoprotein (HDL) in humans. He also identified the first mutations
underlying Lipoprotein Lipase (LPL) deficiency and developed gene
therapy approaches to treat this condition resulting in the first
approved gene therapy product (Glybera) in a major market. He is
the most cited author in the world on the ABCA1 gene and
Huntington's disease. Dr. Hayden is also a Killam Professor at the
University of Columbia.
Dr. Hayden has been working with Oxford Biomedica on a
consultancy basis for the past year and has provided great insight
to the Board and Senior Executive team, he will therefore be
joining the Board of Directors as a Non-Independent Director. The
Board intends to continue to strengthen and diversify the Board
having initiated a search for an additional independent
Non-Executive Director, targeting the selection of female and
ethnically diverse candidates.
There are no other disclosures required to be made in accordance
with LR 9.6.13R.
Dr. Roch Doliveux , Non-Executive Chairman of Oxford Biomedica,
said: "On behalf of the Board, I would like to welcome Michael to
Oxford Biomedica. Bringing with him decades of industry defining
scientific contributions and achievements, including developing the
world's first approved gene therapy treatment, he will be a
formidable asset on the Board as we continue to deliver life
changing gene therapy treatments to people in need. Following
Michael's appointment, we will continue to bolster the Board with
diversity remaining a key element."
Dr. Michael Hayden added: "Having been impressed by the Group's
science and its leading lentiviral vector platform for many years,
I am delighted to be able to join Oxford Biomedica. I look forward
to working closely with the Board to maximise the value of its
technologies and product pipeline at a time where gene and cell
therapy is at the forefront of transforming and improving the
quality of life for people, not to mention its vital applicability
recently in the COVID-19 pandemic."
As of 15 July 2021, the members of the Oxford Biomedica Board of
Directors will be as follows:
Dr. Roch Doliveux, Non-Executive Chairman
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Stuart Henderson, Deputy Chairman and Senior Independent
Director
Professor Dame Kay Davies, Independent Non-Executive
Director
Robert Ghenchev, Non-Executive Director
Dr. Heather Preston, Independent Non-Executive Director
Dr. Sam Rasty, Independent Non-Executive Director
Dr. Michael Hayden, Non-Executive Director
-Ends-
References
(1)
https://pharmaintelligence.informa.com//media/informa-shop-window/pharma/whitepapers/completed-trials-analysis-2017-whitepaper_pharma_intelligence.pdf
(2)
https://www.med.ubc.ca/awards-honours/michael-hayden-listed-among-20th-century-canadians-who-changed-the-world/
Enquiries:
Oxford Biomedica plc T: +44 (0)1865 783 000
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 954 161 / E: ir@oxb.com
Catherine Isted, Head of Corporate
Development & IR
T: +44 (0)20 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, cell
and gene therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders and liver diseases. The
Group has also entered into a number of partnerships, including
with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the
UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in
other potential gene and cell therapy products. Additionally the
group has signed a 3 year master supply and development agreement
with AstraZeneca for large-scale manufacturing of the adenoviral
based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across
several locations in Oxfordshire, UK and employs more than 670
people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFIFVEDEIELIL
(END) Dow Jones Newswires
July 15, 2021 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024